Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the <i>EGFR</i> T790M Mutation After Failure of Initial EGFR-TKI Treatment - Concepedia

Concepedia

Publication | Open Access

Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the <i>EGFR</i> T790M Mutation After Failure of Initial EGFR-TKI Treatment

DOI Full Paper Access

35

Citations

14

References

2018

Year

Hiromi Furuta, Takehiro Uemura, Tatsuya Yoshida, Makiko Kobara, Teppei Yamaguchi, Naohiro Watanabe, Junichi Shimizu, Yoshitsugu Horio, Hiroaki Kuroda, Yukinori Sakao,

Anticancer Research

Abstract

Osimertinib is a safe and effective treatment option for elderly patients with advanced NSCLC who harbor the EGFR mutation.

References

	Year	Citations

Page 1